Dr. Steven Ryder FACP

Steve joined Rallybio in January 2019. He has more than 30 years of leadership experience in global healthcare development and a proven track record in the rare disease space.

Prior to joining Rallybio, Steve served as Senior Vice President, Chief Development Officer at Alexion Pharmaceuticals, where he led the global development, registration, and approval of new drug candidates for rare diseases, and contributed to the overall growth of the company. Previously, he was founding President, Astellas Pharma Global Development, and spent 21 years on development teams at Pfizer. Steve is the past-President and current Board member of the American Society of Clinical Pharmacology and Therapeutics, has served as the industry representative on the FDA’s Endocrinologic and Metabolic Drug Advisory Committee, and has held leadership positions within the Biotechnology Innovation Organization (BIO) and Pharmaceutical Research and Manufacturers of America (PhRMA).

Steve received his MD from the Icahn School of Medicine at Mount Sinai.